214 related articles for article (PubMed ID: 37794465)
1. Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study.
Peng ZY; Yang CT; Lin WH; Yao WY; Ou HT; Kuo S
Cardiovasc Diabetol; 2023 Oct; 22(1):272. PubMed ID: 37794465
[TBL] [Abstract][Full Text] [Related]
2. Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data.
Yang CT; Yao WY; Ou HT; Kuo S
Diabetes Res Clin Pract; 2023 Apr; 198():110625. PubMed ID: 36924833
[TBL] [Abstract][Full Text] [Related]
3. Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework.
Yang CT; Yao WY; Yang CY; Peng ZY; Ou HT; Kuo S
J Intern Med; 2024 Mar; 295(3):357-368. PubMed ID: 37994187
[TBL] [Abstract][Full Text] [Related]
4. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
6. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
7. Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
Bai S; Lin C; Jiao R; Cai X; Hu S; Lv F; Yang W; Zhu X; Ji L
Eur J Intern Med; 2023 Mar; 109():79-88. PubMed ID: 36628824
[TBL] [Abstract][Full Text] [Related]
8. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
[TBL] [Abstract][Full Text] [Related]
9. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.
Yang CY; Chen YR; Ou HT; Kuo S
Cardiovasc Diabetol; 2021 Jan; 20(1):21. PubMed ID: 33468131
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
[TBL] [Abstract][Full Text] [Related]
12. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
13. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
[TBL] [Abstract][Full Text] [Related]
14. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.
Lin Y; Wang TH; Tsai ML; Wu VC; Tseng CJ; Lin MS; Li YR; Chang CH; Chou TS; Tsai TH; Yang NI; Hung MJ; Chen TH
Cardiovasc Diabetol; 2023 Mar; 22(1):60. PubMed ID: 36932379
[TBL] [Abstract][Full Text] [Related]
15. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Schechter M; Melzer Cohen C; Fishkin A; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Chodick G; Clark A; Abrahamsen TJ; Lawson J; Karasik A; Mosenzon O
Cardiovasc Diabetol; 2023 May; 22(1):126. PubMed ID: 37244998
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Nov; 20(1):222. PubMed ID: 34774054
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
19. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
Lajara R
Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]